{"protocolSection":{"identificationModule":{"nctId":"NCT03997292","orgStudyIdInfo":{"id":"K201707"},"organization":{"fullName":"General Hospital of Shenyang Military Region","class":"OTHER"},"briefTitle":"Intravenous Thrombolysis Registry for Acute Ischemic Stroke in China","officialTitle":"Intravenous ThrombolysisRegistry for Acute Ischemic Stroke in China"},"statusModule":{"statusVerifiedDate":"2019-06","overallStatus":"WITHDRAWN","whyStopped":"The study has been terminated due to key change of protocol","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2018-03-01","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2020-09-01","type":"ESTIMATED"},"completionDateStruct":{"date":"2020-09-01","type":"ESTIMATED"},"studyFirstSubmitDate":"2017-11-14","studyFirstSubmitQcDate":"2019-06-21","studyFirstPostDateStruct":{"date":"2019-06-25","type":"ACTUAL"},"lastUpdateSubmitDate":"2019-06-21","lastUpdatePostDateStruct":{"date":"2019-06-25","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Hui-Sheng Chen","investigatorTitle":"Neurology Chief","investigatorAffiliation":"General Hospital of Shenyang Military Region"},"leadSponsor":{"name":"General Hospital of Shenyang Military Region","class":"OTHER"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"To analyze the real situation of intravenous thrombolysis in acute ischemic stroke in China","detailedDescription":"Compare the efficacy and safety of different thrombolytic drugs; Analysis of patients during hospital treatment of adverse events and complications; Analysis of factors that affect the effectiveness of treatment; Evaluate the pharmacological benefits of different thrombolytic drugs"},"conditionsModule":{"conditions":["Ischemic Stroke"],"keywords":["alteplase; urokinase; intravenous thrombolysis"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"COHORT","timePerspective":"PROSPECTIVE"},"bioSpec":{"retention":"SAMPLES_WITH_DNA","description":"blood"},"enrollmentInfo":{"count":0,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Alteplase group","description":"According to 0.6-0.9mg / kg alteplase (maximum can not exceed 90mg), of which 10% intravenous injection, the remaining 60 minutes intravenous infusion","interventionNames":["Drug: Alteplase"]},{"label":"Urokinase group","description":"1.2-1.5 million U dissolved in 100ml sodium chloride injection, 30 minutes intravenously End","interventionNames":["Drug: Urokinase"]}],"interventions":[{"type":"DRUG","name":"Alteplase","description":"According to 0.6-0.9mg / kg alteplase (maximum can not exceed 90mg), of which 10% intravenous injection, the remaining 60 minutes intravenous infusion.","armGroupLabels":["Alteplase group"]},{"type":"DRUG","name":"Urokinase","description":"1.2-1.5 million U dissolved in 100ml sodium chloride injection, 30 minutes intravenously.","armGroupLabels":["Urokinase group"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"mRS of 90 days after thrombolysis","description":"Proportion of patients with mRS = 0-1 points 90 days after thrombolysis","timeFrame":"Month 3"}],"secondaryOutcomes":[{"measure":"Evaluation of Adverse events","description":"Symptomatic intracranial hemorrhage conversion rate; Liver and kidney dysfunction; Bleeding gums; Skin mucous membrane bleeding","timeFrame":"Year 1"}],"otherOutcomes":[{"measure":"Economic evaluation","description":"The cost-effectiveness of different thrombolytic drugs","timeFrame":"Day 14"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 1) age\\> 18 years old;\n* 2) meet the diagnostic criteria of China 2014 guidelines for the diagnosis and treatment of acute ischemic stroke;\n* 3) no history of first sepsis or previous cerebral infarction sequelae (mRS ≤ 1);\n* 4) within 3 hours of onset;\n* 5) Have measurable neurological deficits;\n* 6) Patients or legal guardians can understand and sign informed consent.\n\nExclusion Criteria:\n\n* Absolute exclusion criteria:\n* 1) history of head trauma or stroke within the last 3 months;\n* 2) suspected subarachnoid hemorrhage;\n* 3) history of previous intracranial hemorrhage;\n* 4) intracranial tumor, arteriovenous malformation or aneurysm ;\n* 5) recent intracranial or intraspinal surgery;\n* 6) arterial puncture at an incurable site within the last 7 days;\n* 7) elevated blood pressure: systolic blood pressure ≥180 mm Hg, or diastolic blood pressure ≥100 mm Hg;\n* 8) Internal bleeding;\n* 9) acute bleeding tendency, including platelet count less than 100 × 109 / L or other conditions;\n* 10) heparin treatment within 48 h (APTT is outside the upper limit of normal range);\n* 11) oral anticoagulant, INR\\> 1.7 Or PT\\> 15S;\n* 12) are currently using thrombin inhibitors or factor Xa inhibitors, various sensitive laboratory abnormalities (such as APTT, INR, platelet count, ECT; TT or appropriate factor Xa activity assays) ;\n* 13) Blood glucose \\<50 mg / dl (2.7 mmol / L);\n* 14) CT suggestive of multiple cerebral infarction (low density range\\> 1/3 of the cerebral hemispheres) ;\n* 15) Other conditions considered unsuitable for inclusion in this clinical study;\n* 16) 3 months or are participating in other clinical trials;\n* 17) combined with severe systemic disease is expected to survive less than three months.\n* Relative exclusion criteria:\n* 1) severe stroke (NIHSS\\> 25 points);\n* 2) pregnancy;\n* 3) neurological deficits after epileptic seizures;\n* 4) major surgery or severe trauma within the last 14 days;\n* 5) Urethral hemorrhage;\n* 6) Myocardial infarction within the last 3 months;","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"Thrombolytic patients with acute ischemic stroke within 3 hours of onset","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"overallOfficials":[{"name":"Huisheng Chen, doctor","affiliation":"Neurology Chief","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"General Hospital of Shenyang Military Region","city":"Shenyang","state":"Liaoning","country":"China","geoPoint":{"lat":41.79222,"lon":123.43278}}]},"ipdSharingStatementModule":{"ipdSharing":"UNDECIDED"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000007238","term":"Infarction"},{"id":"D000009336","term":"Necrosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000010959","term":"Tissue Plasminogen Activator"}],"ancestors":[{"id":"D000005343","term":"Fibrinolytic Agents"},{"id":"D000050299","term":"Fibrin Modulating Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"}],"browseLeaves":[{"id":"M13539","name":"Tissue Plasminogen Activator","asFound":"Patient Reported Outcomes","relevance":"HIGH"},{"id":"M13538","name":"Plasminogen","relevance":"LOW"},{"id":"M8163","name":"Fibrinolytic Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}